Compared to Estimates, Walgreens (WBA) Q3 Earnings: A Look at Key Metrics

Walgreens Boots Alliance (WBA) reported $38.99 billion in revenue for the quarter ended May 2025, representing a year-over-year increase of 7.3%. EPS of $0.38 for the same period compares to $0.63 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $36.61 billion, representing a surprise of +6.49%. The company delivered an EPS surprise of +11.76%, with the consensus EPS estimate being $0.34.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- U.S. Retail Pharmacy: $30.72 billion compared to the $28.76 billion average estimate based on four analysts. The reported number represents a change of +7.8% year over year. Revenues- U.S. Healthcare: $2.10 billion versus $2.17 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.1% change. Revenues- International: $6.17 billion versus the four-analyst average estimate of $5.74 billion. The reported number represents a year-over-year change of +7.8%. Adjusted operating income (loss)- U.S. Retail Pharmacy: $350 million versus the two-analyst average estimate of $113.67 million. Adjusted operating income (loss)- Corporate and Other: -$60 million versus the two-analyst average estimate of -$52.50 million. Adjusted operating income (loss)- U.S. Healthcare: $54 million versus the two-analyst average estimate of $72.85 million. Adjusted operating income (loss)- International: $214 million versus $196.39 million estimated by two analysts on average. View all Key Company Metrics for Walgreens here>>>Shares of Walgreens have returned +1.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks